Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PhtD_pep19 is a synthetic peptide vaccine candidate derived from the pneumococcal histidine triad protein D (PhtD) of *Streptococcus pneumoniae*. It represents an immunodominant B-cell epitope located within the zinc-binding domain of the PhtD protein. In preclinical studies, PhtD_pep19 has demonstrated the ability to elicit high-avidity antibodies with significant opsonophagocytic killing activity (OPKA) against multiple pneumococcal serotypes, including 1, 3, and 19A. Immunization with this peptide, either alone or as part of a mixture, has been shown to protect murine models against lethal sepsis caused by highly virulent pneumococcal strains. The peptide is being investigated as a novel immunoreactive component for the development of next-generation, polysaccharide-independent pneumococcal vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PhtD_pep19.